Analysts Set Scholar Rock Holding Co. (NASDAQ:SRRK) Target Price at $40.43

Scholar Rock Holding Co. (NASDAQ:SRRK - Get Free Report) has earned a consensus rating of "Buy" from the seven brokerages that are covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $40.43.

Several equities research analysts have commented on the stock. Truist Financial raised their price target on shares of Scholar Rock from $36.00 to $45.00 and gave the company a "buy" rating in a research note on Monday, November 25th. HC Wainwright lifted their target price on Scholar Rock from $40.00 to $50.00 and gave the company a "buy" rating in a research note on Tuesday, November 26th. Finally, Wedbush reissued an "outperform" rating and issued a $47.00 price target on shares of Scholar Rock in a research note on Wednesday, January 29th.

Scholar Rock Stock Performance

Shares of SRRK stock traded up $1.09 during trading hours on Friday, reaching $38.04. The stock had a trading volume of 479,695 shares, compared to its average volume of 909,602. The firm has a market capitalization of $3.56 billion, a PE ratio of -16.19 and a beta of 0.50. The firm has a 50-day simple moving average of $42.02 and a 200-day simple moving average of $28.02. Scholar Rock has a twelve month low of $6.76 and a twelve month high of $46.98. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88.

Insider Activity

In other news, major shareholder Public Equities L.P. Invus sold 409,433 shares of Scholar Rock stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $38.49, for a total value of $15,759,076.17. Following the transaction, the insider now owns 10,850,005 shares of the company's stock, valued at $417,616,692.45. The trade was a 3.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Edward H. Myles sold 12,539 shares of the business's stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $44.20, for a total transaction of $554,223.80. Following the completion of the sale, the chief financial officer now owns 148,549 shares in the company, valued at $6,565,865.80. The trade was a 7.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 458,974 shares of company stock worth $17,948,788. 19.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Scholar Rock

Large investors have recently modified their holdings of the stock. FMR LLC lifted its holdings in shares of Scholar Rock by 33.7% during the fourth quarter. FMR LLC now owns 13,635,261 shares of the company's stock valued at $589,316,000 after purchasing an additional 3,439,215 shares during the last quarter. Marshall Wace LLP raised its holdings in Scholar Rock by 1,283.7% during the 4th quarter. Marshall Wace LLP now owns 2,945,408 shares of the company's stock worth $127,301,000 after buying an additional 2,732,546 shares during the period. Norges Bank purchased a new stake in Scholar Rock during the fourth quarter valued at about $86,043,000. Fairmount Funds Management LLC purchased a new stake in Scholar Rock during the fourth quarter valued at about $84,839,000. Finally, Adage Capital Partners GP L.L.C. acquired a new position in shares of Scholar Rock in the fourth quarter worth about $68,930,000. 91.08% of the stock is owned by institutional investors.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.